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Erlotinib-HCl is a quinazoline derivative used as a drug in the therapy of non-small-cell lung can-
cer. The present study was conducted to compare the subacute toxicity induced by Erlotinib-HCl
delivered to rats as nanoparticles and as free drug. Wistar rats were orally administered with a
daily dosage of 200 mg kg−1 Erlotinib-HCl either as free drug or as Poly(D,L-lactic-co-glycolic
acid) (PLGA) encapsulated nanoparticles. After four weeks of treatment, the animals were ana-
lyzed for toxicological changes. Although nanoparticulate form of the drug did not induce any tox-
icity, free drug signiﬁcantly reduced the levels of white blood cells (WBC), red blood cells (RBC)
and haemoglobin, while increasing the levels of neutrophils and corpuscular haemoglobin. More-
over, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were signiﬁcantly
increased in the animals administered with free drug. Histopathological studies conﬁrmed signiﬁ-
cant damage to the internal organs of animals treated with free drug. Whereas, the internal organs
of animals treated with the drug encapsulated in PLGA nanoparticles were more or less similar to
the healthy organs. Our results show that Erlotinib-HCl delivered in the form of nanoparticles has
less toxic effect than the free drug in experimental rats.
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1. INTRODUCTION
Non-small-cell lung cancer accounts for approximately
75% of lung cancers and a leading cause of cancer-
related death in men and women with overall cure rates
of less than 15%.1 Recent molecular biology studies have
revealed that aggressive tumor activity of non-small-cell
lung cancer is generally correlated with the over expres-
sion of the Epidermal Growth Factor Receptor (EGFR)
tyrosine kinase.1 Tyrosine kinase plays a critical role in
many cell signaling pathways that inﬂuence cell divi-
sion, apoptosis, motility and adhesion.2 Activated forms of
tyrosine kinases can enhance tumor cell proliferation and
growth, induce antiapoptotic effects and promote angio-
genesis and metastasis. Erlotinib-HCl speciﬁcally inhibits
tyrosine kinase receptors from binding to their legends,
thus blocks the downstream signaling pathways and tumor
activity. Hence, this compound is currently used in the
therapy of non-small-cell lung cancer.34
∗Author to whom correspondence should be addressed.
Erlotinib-HCl is available in the market as ﬁlm coated
tablet for oral administration. This route is the most
preferred and easy way of drug delivery. However, the
drug administered through this route is poorly available
mainly because of the biopharmaceutical (poor solubil-
ity, poor permeability and/or instability in gastrointesti-
nal environment) and pharmacokinetic (extensive ﬁrst pass
metabolism and/or rapid clearance) hurdles.5 Moreover,
cancer treatments normally require long term drug admin-
istration and the drugs generally attack both normal cells
and cancer cells, when the drug is given as an injection or
in tablet form for a long time.6 As the aforementioned lim-
itations are unavoidable in oral administration, methods to
protect the drug from external harsh conditions (chemical
and enzymatic degradation) of gastro intestinal track and
sustained release are necessary.
Delivery of anticancer agents as nanoparticles has
received much attention due to the unique accumula-
tion behavior of nanoparticles at the tumor site.7–9 In
the nanoparticulate drug delivery, the therapeutic agent
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of interest is encapsulated within the polymer matrix of
biodegradable particles to achieve extended release.1011
When encapsulated within a biodegradable polymer, the
drug is released slowly over a period of time as the poly-
mer degrades. Poly(D,L-lactic-co-glycolic acid) (PLGA)
polymer used in this study is regarded as highly safe
because it is completely metabolized by the body and
approval by the FDA.12 The ﬁnal degradation products
such as lactic and glycolic acids of this polymer are also
completely safe, as they are either excreted by the kid-
neys or enter the Krebs’ cycle and eventually eliminated
as carbon dioxide and water.1314
From the literature it is clear that drugs encapsulated
in PLGA nanoparticles exhibits reduced toxicity to nor-
mal cells/tissues compared to the free drug.1516 Hence,
Erlotinib-HCl was encapsulated in PLGA nanoparticles
and the subacute toxicity in healthy rats was assessed and
compared with the free drug administrated animals in the
current investigation.
2. MATERIALS AND METHODS
2.1. Drug and Chemicals
Erlotinib-HCl was obtained from Ranbaxy Pharmaceuti-
cals (Delhi, India). PLGA with a lactide/glycolide molar
ratio of 50:50 and polyvinyl alcohol (PVA, MW 22,000)
were purchased from Sigma, Germany. Dichloromethane
(DCM) was procured from Ranbaxy laboratory reagent
(India). All reagents used in the present study were of ana-
lytical grade.
2.2. Preparation of Erlotinib-HCl Encapsulated in
PLGA Nanoparticles
The PLGA nanoparticles with Erlotinib-HCl were pre-
pared by sonication-solvent evaporation technique as
described before.17 Brieﬂy, an organic phase consisting of
polymer (PLGA, 10 mg mL−1 and drug (Erlotinib-HCl,
0.5 mg mL−1 dissolved in DCM (5 mL) was prepared.
An emulsion was made by adding an aqueous solution
containing a surfactant (PVA, 1%, 50 mL). This emulsion
was broken down into nanodroplets by sonication (7 min)
and the solvent was evaporated by magnetic stirring at
300 rpm to form a colloidal suspension of PLGA nanopar-
ticles in water. This suspension was centrifuged at 12000 g
for 1.0 h to pellet down the nanoparticles. The pellet was
washed three times with ultra pure water to remove any
free drug.
2.3. Characterization of the Nanoparticles
2.3.1. Zeta Potential
The zeta potential of the formulations was determined by
laser doppler anemometry using a Zetasizer (3000 HS,
Malvern Instruments, UK). For the measurement, 100 L
nanoparticle suspension was diluted to 4 mL with 10 mM
NaCl solution and the pH was adjusted to 8.0 using 0.25 N
NaOH. An electric ﬁeld of 150 mV was applied to observe
the electrophoretic velocity of the particles. All mea-
surements were made at room temperature as described
before.18
2.3.2. Scanning Electron Microscopy (SEM) Analysis
Morphological characterization of nanoparticles was done
by SEM analysis. Samples were prepared by dropping
nanoparticle suspension onto aluminum stubs and allow-
ing them to air-dry before coating with gold. The parti-
cles were then observed in a scanning electron microscope
(JEOL JSM-6400).
2.3.3. Determination of Drug Content of Nanoparticles
In order to determine the dosage for administration, the
drug content of prepared nanoparticles was measured.
Brieﬂy, 20 mg nanoparticles were dissolved in 2.0 mL
dichloromethane. Subsequently, 5.0 mL PBS was added.
The mixture was vortexed for 1.0 min at 2500 rpm and
again for 2.0 h at 1000 rpm. After vortexing, the sus-
pension was brieﬂy centrifuged at 10,000 rpm to pellet
the debris. Absorbance of the supernatant was read in a
spectrophotometer (Shimadzu UV-1700, India) at 348 nm
using PBS as blank. This value was plotted on Erlotinib-
HCl standard graph to determine the drug content of the
nanoformulation.
2.3.4. Encapsulation Efﬁciency and Loading Capacity
The actual loading and encapsulation efﬁciency of
nanoparticles were determined by the following equations.
Encapsulation efﬁciency was deﬁned as the percentage of
determined loading relative to the nominal (theoretical)
loading:19
Encapsulation efﬁciency
= The amount of drug in the nanoparticles
Total amount of drug
×100
Drugloading capacity
= The amount of drug in the nanoparticles
Total amount of nanoparticles weight
×100
Percentage yield
= The amount of recovered nanoparticles
The amount of employedpolymer and drug
×100
2.3.5. In Vitro Drug Release Measurement
Erlotinib-HCl loaded in PLGA nanoparticles (10 mg) were
suspended in 2 mL PBS (pH 7.4) and transferred into a
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dialysis tube. The dialysis tube was then placed into a
100 mL bottle containing 50 mL PBS and the medium
was stirred at 100 rpm at 37 C. Once in every 24 h,
1 mL sample was withdrawn and the accumulated drug
content was measured spectrophotometrically. To compen-
sate the withdrawn sample, 1 mL PBS was added after
each withdrawal.
2.3.6. Evaluation of Toxicity of Encapsulated
Erlotinib-HCl in PLGA Nanoparticles
The subacute toxicity of Erlotinib-HCl loaded PLGA
nanoparticles was evaluated in six weeks old Wistar rats
obtained from Government veterinary college, Chennai.
Use of these animals for experimental purpose has
been approved by the Animal Ethical Committee (CLRI,
Chennai). All the animals were maintained in a room at
25±2 C with 12–12 h light-dark cycle and were fed with
conventional laboratory diet and unlimited supply of drink-
ing water. They were divided into three groups (control,
nano drug and free drug) each containing 5 males and
5 females for experiment. Control group received normal
saline. Nano drug group received 200 mg kg−1 Erlotinib-
HCl encapsulated in PLGA nanoparticles (calculated based
on the drug content of nanoformulation) and free drug
group received 200 mg kg−1 Erlotinib-HCl in the free
form. Treatment for each group was continued for 28 days.
Animals were observed for the development of toxico-
logical signs and symptoms such as mortality, change in
body weight and feed intake throughout the study period.
On day 29 after the beginning of the experiments, blood
sample were collected from the orbital sinus of each ani-
mal. Blood samples for haematological and biochemical
studies were collected in vials containing EDTA and in
vials rinsed with heparin respectively. After blood col-
lection, all the animals were dissected to obtain inter-
nal organs (liver, kidney, adrenal gland, testes, brain and
spleen). Organs were weighed and observed for gross
pathological changes. Heart, lungs, kidney and liver were
preserved in 10% formalin for histopathological studies.
2.3.7. Haematological Analyses
Red blood cells (RBC) and white blood cells (WBC)
content of the blood samples were determined in a haemo-
cytometer. Haematocrit (HCT) and haemoglobin (Hb)
contents were estimated spectrophotometrically using stan-
dard methods. Platelet (Plt) count was made using direct
method and clotting time (coagulation time) by capillary
method. For differential count, blood smear was stained
with Leishman stain and 100 leucocytes were counted
under light microscope. All other haematological param-
eters such as mean corpuscular volume (MCV), mean
corpuscular/cell haemoglobin concentration (MCHC),
lymphocytes (LYM) and neutrophils (N) were estimated in
a haematology analyzer.20
2.3.8. Plasma Biochemical Assays
Plasma was separated from heparinised blood by centrifu-
gation at 3000 rpm for 30 min at 4 C. Total protein
(TP) was estimated by biuret method. Aspartate amino-
transferase (AST), alanine aminotransferase (ALT), alka-
line phosphatase (ALP), total bilirubin (TB) and creatinine
(CRE), were assayed in an autoanalyzer (Erba Smart Lab,
India) by using diagnostic kits (Erba test kits, Transasia,
India).
2.3.9. Histopathological Examination
Internal organs of the experimental animals were ﬁxed in
10% formalin, embedded into parafﬁn and cut into 5 m
thick sections in a microtome. Sections were mounted
on glass slides using standard techniques. After stain-
ing with hematoxylin-eosin, the sections were examined
and photographed under a light microscope equipped for
photography.
3. RESULTS
3.1. Characteristics of Erlotinib-HCl
Encapsulated in PLGA Nanoparticles
Scanning electron micrography of the prepared nanopar-
ticles revealed a homogeneous solid matrix structure
(Fig. 1). Particle size distribution analysis by zetasizer
showed that the mean average of the prepared nanoparti-
cles was 217 nm. Encapsulation efﬁciency of the nanopar-
ticles was found to be 22.86%. The drug loading efﬁciency
of the nanoparticles was 21.75% and the yield of nanopar-
ticles was 42.50%.
3.2. In Vitro Drug Release from Nanoparticles
The percentage of accumulated Erlotinib-HCl after differ-
ent time period is shown as a graph (Fig. 2). After the
initial burst release for about 4 days, the release rate of
300 nm
Fig. 1. Scanning electron micrograph of Erlotinib-HCl loaded in PLGA
nanoparticles (scale bar= 300 nm).
































Fig. 2. The in vitro release proﬁle of Erlotinib-HCl loaded in PLGA
nanoparticles. The error bars indicate the standard deviation of the mean
for 3 experiments.
Erlotinib-HCl from the nanoparticles slowed down. After
12 days, the amount of accumulated Erlotinib-HCl in PBS
was calculated to be 65% of the entrapped drug.
3.3. Changes in Body Weight
Oral administration of Erlotinib-HCl both as nanoparti-
cles and as free drug did not cause mortality during the
experimental period. Although the growth rate of male ani-
mals was not affected (Fig. 3(a)), a reduced growth rate in
female animals was observed when the free form of the
drug was administered (Fig. 3(b)).
3.4. Changes in Internal Organ Weight
There was no change between control and nano drug
groups in the weight of internal organs (liver, brain,
kidneys, spleen, adrenal glands and testes). Whereas, the
weight of liver and kidneys was increased signiﬁcantly in
free drug treated animals (both in male and female groups)
over control and nano drug treated animals (Table I).
Although adrenal weight was not signiﬁcantly different
between treatments in male groups, the weight was signif-
icantly increased in females of free drug group.
3.5. Haematological Changes
Haematological studies showed that there was no signif-
icant change between control and nano drug group with
the exception of HCT content of female animals, which
was signiﬁcantly increased over control. However, signif-
icant changes (either increase or decrease) in most of the
tested heamatological parameters were observed in free
drug treated animals except the MCV. In addition, HCT
content was not affected in male animals but it substan-
tially reduced in female animals. There was a signiﬁcant
decrease in the RBC count in both male and female ani-
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Fig. 3. Changes in the body weight of male (a) and female (b) animals
during the treatment by 28 days.
3.6. Biochemical Changes
There was no signiﬁcant change in the tested parameters
between control and nano drug treated animals. Neverthe-
less an increased level of ALP was observed in the female
animals treated with nano drug compared to control.
Aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALP), and creatinine
levels were signiﬁcantly increased in animals administered
with free drug compared to control and nano drug groups
(Table III).
3.7. Histopathological Changes
The histological sections of heart, lungs, kidney and
liver of control animals are shown in Figures 4(a)–(d).
Similar histological sections of organs of animals admin-
istered with nanoparticles with Erlotinib-HCl are shown
in Figures 4(e)–(h). Comparison of these photomicro-
graphs clearly shows that there were no toxicity-induced
changes in the animals administered with nanoparticles
with Erlotinib-HCl. However, in the organs of animals
administered with free drug many toxicity related changes
were observed (Figs. 4(i–l)). As seen in the ﬁgure, car-
diac muscle ﬁbres were completely damaged in the heart
(Fig. 4(i)), normal architecture was lost in lung (Fig. 4(j)),
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Table I. Changes in the internal organ weight (g) of control and treated animals after 28 days of drug administration.
Male groups Female groups
Control Nano drug Free drug Control Nano drug Free drug
Liver 7.5±0.27 7.49±0.29 9.2±0.54a 6.46±0.50 6.50±0.19 8.65±0.15a
Brain 1.84±0.07 1.82±0.05 1.79±0.04 1.79±0.02 1.88±0.05 1.86±0.05
Kidneys 1.95±0.05 1.97±0.07 2.26±0.13a 1.54±0.06 1.44±0.06 2.55±0.06a
Spleen 0.62±0.07 0.61±0.08 0.58±0.12 0.76±0.13 0.56±0.04 0.65±0.08
Adrenal 0.05±0.01 0.05±0.02 0.06±0.01 0.07±0.01 0.071±0.01 0.23±0.16a
Testes 2.67±0.13 2.63±0.15 2.85±0.11 — — —
The values are expressed as mean±SEM of 5 animals. adenotes signiﬁcant at the level of p < 005.
Table II. Haematological observation of control and treated animals after 28 days of drug administration.
Male groups Female groups
Parameters Control Nano drug Free drug Control Nano drug Free drug
WBC (103/l) 11.60±0.36 10.20±0.12 9.60±0.15a 6.97±0.62 6.53±0.18 8.87±0.41a
RBC (106/l) 7.95±0.43 7.27±4.50 4.79±0.16a 7.15±0.2 6.49±0.16 6.1±0.12a
HB (g/dl) 12.20±0.27 12.17±0.23 11.63±0.20a 11.33±0.35 10.90±0.56 12.07±0.69
HCT (%) 37.97±1.09 36.40±0.32 36.50±0.68 37.23±1.27 33.17±0.66a 29.50±0.32a
MCV (ﬂ) 50.60±0.56 49.90±0.46 50.17±0.62 50.53±0.62 51.73±1.29 51.13±1.17
MCHC (%) 32.43±0.44 33.03±0.27 36.83±1.36a 34.07±0.12 33.60±1.01 34.77±0.69
PLT (105/l) 885.33±8.57 730.33±34.38 568.00±12.58a 804.0±28.01 720.0±14.42 575.67±21.18a
LYM (%) 87.93±0.32 86.57±2.34 58.27±1.43a 78.4±0.84 78.27±2.21 83.43±0.93a
N (%) 7.40±2.2 8.40±0.9 10.80±1.2a 12.40±2.2 11.40±1.2 14.00±0.9a
The values are expressed as mean±SEM of 5 animals. adenotes signiﬁcant at the level of p < 005.
Table III. Biochemical changes in animals after 28 days of drug administration.
Male groups Female groups
Parameters Control Nano drug Free drug Control Nano drug Free drug
TB (mg/dl) 0.85±0.03 0.95±0.15 1.25±0.02 0.97±0.02 0.93±0.02 1.10±0.12
TP (mg/dl) 5.43±0.02 5.56±0.15 4.07±0.02a 6.47±0.34 6.42±0.28 6.40±0.24
AST (IU/L) 115.5±9.6 113.2±10.2 135.5±9.6a 131.0±7.2 142.4±28.2 153.3±12.3a
ALT (IU/L) 56.5±6.7 57.2±5.2 60.2±4.2a 53.7±4.9 54.1±4.0 67.2±4.2a
ALP (IU/L) 109.0±2.52 114.0±3.46 117.33±1.76a 160.67±1.2 165.00±1.15a 169.00±1.15a
CRE (mg/dl) 0.88±0.02 1.27±0.02 1.47±0.12a 0.96±0.02 1.20±0.02 1.67±0.15a
The values are expressed as mean±SEM of 5 animals. adenotes signiﬁcant at the level of p < 005.
hepatocytes were damaged in liver (Fig. 4(k)) and tubular
degeneration with basophilic foci was found in the kidneys
(Fig. 4(l)).
4. DISCUSSION
In the recent years, oral delivery of anti cancer drugs
encapsulated in polymeric nanoparticles has gained much
attention. This is mainly due to the potential of nanopar-
ticles to protect the entrapped drug molecules from the
harsh conditions (chemical and enzymatic degradation) of
gastro intestinal track.2122 In addition to this, the drug
is delivered directly into systemic circulation through the
lymphatics circumventing the ﬁrst pass metabolism, as
nanoparticle uptake generally occurs through “M-cells” of
the Peyer’s patches via receptor mediated endocytosis.5
In the present study, we have encapsulated Erlotinib-
HCl with PLGA and evaluated the subacute toxicity in
rats. Erlotinib-HCl nanoparticles were prepared by emul-
sion solvent evaporation method which enabled us to
obtain spherical, discrete spheres with a size ranging from
200–300 nm as revealed by scanning electron microscopy
(Fig. 1). After characterizing the nanoparticles, we studied
the in vitro release proﬁle (Fig. 2). The in vitro release
proﬁle of Erlotinib-PLGA nanoparticles had two distinct
phases. The initial burst release phase (for about 4 days)
might be due to the dissolution and diffusion of the drug
that was poorly entrapped in the polymer matrix. On the
other hand, the slower and continuous release after this
initial burst can be attributed to the diffusion of the drug
localized in the core of the nanoparticles. Such bipha-
sic release proﬁle of the entrapped therapeutic agent from
PLGA nanoparticles has been reported before.519
Inhibitors like Erlotinib that target EGFR, display the
broadest spectrum of adverse effects on skin and hair,
including folliculitis, paronychia, facial hair growth, facial
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(a)
(e)
(i) (j) (k) (l)
(f) (g) (h)
(b) (c) (d)
Fig. 4. Photomicrographs of internal organs (heart, lung, liver and kidney) of control and treated animals. (a) Heart of a control animal; (b) Lung of a
control animal; (c) Kidney of a control animal; (d) Liver of a control animal; (e) Heart of a nano with Erlotinib-HCl treated animal, (f) Lung of a nano
with Erlotinib-HCl treated animal; (g) Kidney of a nano with Erlotinib-HCl treated animal and; (h) Liver of a nano with Erlotinib-HCl treated animal.
Note the normal architecture in the organs of control and nano Erlotinib-HCl treated animals. (i) Heart of a free Erlotinib-HCl treated animal showing
cardiac muscle ﬁbres were completely damaged; (j) Lung of a free Erlotinib-HCl treated animal showing normal architecture was lost; (k) Kidney of
a free Erlotinib-HCl treated animal showing tubular degeneration with basophilic foci and; (l) Liver of a free Erlotinib-HCl treated animal showing
damaged hepatocytes.
erythema, frontal alopecia and induce haematological side
effects like anaemia, thrombopenia and neutropenia.23
Adverse effects of chemotherapeutic agents are gener-
ally accompanied by a loss of body weight or reduced
body weight gain, changes in the weight of vital organs,
disturbance in haematological, biochemical parameters
etc. Hence, rats administered with Erlotinib-HCl in the
nano and free forms were compared in these toxiclolog-
ical parameters. In our preliminary repeated dose experi-
ments, we found that oral administration of 200 mg kg−1
Erlotinib-HCl encapsulated in PLGA nanoparticles was
well tolerated by rats. Hence, we have chosen this dosage
of both nanoencapsulated and free drug for subactue toxi-
city comparison studies.
The data obtained in the present study clearly indi-
cate that administration of 200 mg kg−1 Erlotinib-HCl
has induced systemic toxicity in rats. For e.g., haema-
tological analyses have shown that these animals have
developed anaemia and reduced immunity. It has already
been reported that Erlotinib causes a reduction in RBC
with a compensatory increase in reticulocytes, white blood
cells and primarily neutrophils in rats.24 Another impor-
tant adverse effect of chemotherapy is the tissue dam-
age or necrosis of organs which is generally accompanied
by increase in the levels of several non-functional plasma
enzymes such as AST, ALT and ALP. These enzymes
are among several other enzymes used for the diagnos-
tic purpose,25 since these enzymes present in liver and
heart cells and are normally released into blood only when
these organs are damaged or undergo tissue necrosis. In
the present study also levels of these enzymes have signif-
icantly increased in the plasma of rats administered with
free Erlotinib-HCl indicating severe damage to liver and/or
heart tissue.
The toxicological changes in the free drug treated ani-
mals were further apparent in the histopathological studies.
We observed tissue damage or necrosis in all the tested
internal organs, namely heart, lung, kidney and liver. As
seen in the photomicrographs, cardiac muscle ﬁbres were
completely damaged in the heart (Fig. 4(i)), normal archi-
tecture was lost in lung (Fig. 4(j)), tubular degeneration
with basophilic foci was found in the kidneys (Fig. 4(k))
and hepatocytes were damaged in liver (Fig. 4(l)).
Although toxicity symptoms were apparent in animals
administered with free Erlotinib-HCl, there was no sign of
toxicity observed in animals administered with nanoencap-
sulated form of the drug of the same dose. All the haema-
tological and biochemical parameters tested were normal
and histopathological studies conﬁrmed normal architec-
ture of the tested internal organs. Hence, our study clearly
show that nanoencapsulation with PLGA protects the ani-
mals from Erlotinib-HCl induced toxicity at a concentra-
tion which is otherwise not tolerated by these animals
in repeated doses. Nanoparticles have made a tremen-
dous impact in the treatment of various types of cancer,
as evidenced by the numerous nanoparticle-based drugs
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and delivery systems that are in clinical use.26 Several
anti-cancer drugs including paclitaxel,2728 doxorubicin,29
5-ﬂuorouracil30 and dexamethasone31 have been success-
fully formulated using nanomaterials.
Although many reports are available on nanoformu-
lations of anticancer drugs, in vivo toxicity studies are
relatively scarce. In this context, cyclosporine-induced
nephrotoxicity could be signiﬁcantly reduced by nanoen-
capsulation of this drug with PLGA.32 Similarly, car-
diac toxicity of doxorubicin was dramatically reduced
by PLGA encapsulation.1533 Moreover, estradiol loaded
PLGA nanoparticles was effective in improving the
oral bioavailability and decreasing the dosing frequency,
thereby minimizing the dose dependent adverse effects in
male Sprague Dawley (SD) rats.34 All these reports support
our observation that PLGA nanoencapsulation can signiﬁ-
cantly reduce drug-induced toxicity. The reduced toxicity
of Erlotinib-HCl loaded in PLGA nanoparticles may be
attributed to the pharmacokinetics of the nanoformulation,
which warrants further investigation.
5. CONCLUSION
The results of this study clearly indicate that there
is a great potential for nanoparticulate delivery of
Erlotinib-HCl in minimizing drug-induced toxicity. How-
ever, extensive studies in terms of chronic toxicity, phar-
macokinetic and pharmacodynamic are needed before
establishing nanoparticle-mediated delivery of this drug.
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